These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

491 related articles for article (PubMed ID: 18186499)

  • 1. Red blood cell transfusions and iron overload in the treatment of patients with myelodysplastic syndromes.
    Jabbour E; Kantarjian HM; Koller C; Taher A
    Cancer; 2008 Mar; 112(5):1089-95. PubMed ID: 18186499
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Iron status and treatment modalities in transfusion-dependent patients with myelodysplastic syndromes.
    Delforge M; Selleslag D; Triffet A; Mineur P; Bries G; Graux C; Trullemans F; MacDonald K; Abraham I; Pluymers W; Ravoet C
    Ann Hematol; 2011 Jun; 90(6):655-66. PubMed ID: 21318574
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Red blood cell transfusion therapy and iron chelation in patients with myelodysplastic syndromes.
    Malcovati L
    Clin Lymphoma Myeloma; 2009; 9 Suppl 3():S305-11. PubMed ID: 19778858
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of transfusional iron overload in patients with myelodysplastic syndrome or severe anemia: data from multicenter clinical practices.
    Raptis A; Duh MS; Wang ST; Dial E; Fanourgiakis I; Fortner B; Paley C; Mody-Patel N; Corral M; Scott J
    Transfusion; 2010 Jan; 50(1):190-9. PubMed ID: 19719471
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The clinical, quality of life, and economic consequences of chronic anemia and transfusion support in patients with myelodysplastic syndromes.
    Platzbecker U; Hofbauer LC; Ehninger G; Hölig K
    Leuk Res; 2012 May; 36(5):525-36. PubMed ID: 22300879
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The deleterious effects of iron overload in patients with myelodysplastic syndromes.
    Dreyfus F
    Blood Rev; 2008 Dec; 22 Suppl 2():S29-34. PubMed ID: 19059054
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improvement of iron-mediated oxidative DNA damage in patients with transfusion-dependent myelodysplastic syndrome by treatment with deferasirox.
    Kikuchi S; Kobune M; Iyama S; Sato T; Murase K; Kawano Y; Takada K; Ono K; Kaneko Y; Miyanishi K; Sato Y; Hayashi T; Takimoto R; Kato J
    Free Radic Biol Med; 2012 Aug; 53(4):643-8. PubMed ID: 22705364
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of iron overload in myelodysplastic syndromes.
    Fenaux P; Rose C
    Blood Rev; 2009 Dec; 23 Suppl 1():S15-9. PubMed ID: 20116635
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of transfusion dependency and secondary iron overload on the survival of patients with myelodysplastic syndromes.
    Malcovati L
    Leuk Res; 2007 Dec; 31 Suppl 3():S2-6. PubMed ID: 18037415
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Iron overload in MDS-pathophysiology, diagnosis, and complications.
    Gattermann N; Rachmilewitz EA
    Ann Hematol; 2011 Jan; 90(1):1-10. PubMed ID: 20938663
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Myocardial iron loading by magnetic resonance imaging T2* in good prognostic myelodysplastic syndrome patients on long-term blood transfusions.
    Chacko J; Pennell DJ; Tanner MA; Hamblin TJ; Wonke B; Levy T; Thomas PW; Killick SB
    Br J Haematol; 2007 Sep; 138(5):587-93. PubMed ID: 17610536
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Consensus statement on iron overload in myelodysplastic syndromes.
    Bennett JM;
    Am J Hematol; 2008 Nov; 83(11):858-61. PubMed ID: 18767130
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transfusion independence in patients with myelodysplastic syndromes: impact on outcomes and quality of life.
    Balducci L
    Cancer; 2006 May; 106(10):2087-94. PubMed ID: 16607649
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Erythropoiesis-stimulating agents versus RBC transfusion in MDS: comparison of long-term outcomes.
    Mundle SD
    Future Oncol; 2007 Aug; 3(4):397-403. PubMed ID: 17661714
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical consequences of iron overload from chronic red blood cell transfusions, its diagnosis, and its management by chelation therapy.
    Shander A; Sazama K
    Transfusion; 2010 May; 50(5):1144-55. PubMed ID: 20088842
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Myelodysplastic syndromes and the role of iron overload.
    Harvey RD
    Am J Health Syst Pharm; 2010 Apr; 67(7 Suppl 2):S3-9. PubMed ID: 20332503
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Guidelines on iron chelation therapy in patients with myelodysplastic syndromes and transfusional iron overload.
    Gattermann N
    Leuk Res; 2007 Dec; 31 Suppl 3():S10-5. PubMed ID: 18037413
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of transfusion dependency on survival in patients with early myelodysplastic syndrome without excess of blasts.
    Cermak J; Kacirkova P; Mikulenkova D; Michalova K
    Leuk Res; 2009 Nov; 33(11):1469-74. PubMed ID: 19646756
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hematopoietic recovery after administration of deferasirox for transfusional iron overload in a case of myelodysplastic syndrome.
    OKABE H; SUZUKI T; OMORI T; MORI M; UEHARA E; HATANO K; UEDA M; MATSUYAMA T; TOSHIMA M; QZAKI K; NAGAI T; MUROI K; OZAWA K
    Rinsho Ketsueki; 2009 Nov; 50(11):1626-9. PubMed ID: 20009438
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Understanding iron overload: screening, monitoring, and caring for patients with transfusion-dependent anemias.
    Ault P; Jones K
    Clin J Oncol Nurs; 2009 Oct; 13(5):511-7. PubMed ID: 19793708
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.